PCSK9-IN-2 is primarily used in research settings to study its potential as a therapeutic agent for managing cholesterol levels. It functions as an inhibitor of PCSK9, a protein that plays a key role in regulating LDL cholesterol in the bloodstream. By blocking PCSK9, this compound helps increase the liver's ability to remove LDL cholesterol, thereby reducing its levels in the blood. This mechanism makes it a promising candidate for the development of treatments aimed at preventing cardiovascular diseases, such as atherosclerosis and heart attacks, which are often linked to high cholesterol. Researchers are actively exploring its efficacy and safety in preclinical studies to assess its potential for future clinical applications.